Rapid safe tranquillisation for acutely disturbed people attending public psychiatric emergency clinics in Rio de Janeiro

Submission date Recruitment status [X] Prospectively registered 08/03/2002 No longer recruiting [X] Protocol [] Statistical analysis plan Registration date Overall study status 08/03/2002 Completed [X] Results [] Individual participant data Last Edited Condition category 21/05/2019 Mental and Behavioural Disorders

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Gisele Huf

Contact details

Oswaldo Cruz Foundation
National School of Public Health
Manguinhos
Av. Leopoldo Bulhões 1480/sala 816
Rio de Janeiro
Brazil
RJ 21041-210
+55 (21) 2598 2622
gisele@ensp.fiocruz.br

Additional identifiers

Protocol serial number N/A

Study information

Scientific Title

Rapid safe tranquillisation for acutely disturbed people attending public psychiatric emergency clinics in Rio de Janeiro

Acronym

TREC-Rio = Rapid Tranquillisation Clinical Trial (Tranquilizacao Rapida-Ensaio Clinico)

Study objectives

TREC-Rio will compare midazolam with haloperidol-promethazine mix for treatment of agitated patients in emergency psychiatric rooms of Rio de Janeiro, Brazil.

Ethics approval required

Old ethics approval format

Ethics approval(s)

TREC-Rio has been approved by the ethics committees of institutions in charge of research and local ethics committees of each hospital involved.

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Serious mental illnesses combined with overt aggression or violence

Interventions

- 1. Haloperidol (up to 10 mg intramuscular [IM]) with promethazine (up to 50 mg IM)
- 2. Midazolam (up to 15 mg IM)

Doses are not fixed and are at the discretion of the attending doctors.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Midazolam, haloperidol-promethazine

Primary outcome(s)

Tranquillisation at 20 minutes.

Key secondary outcome(s))

Effects on other measures of morbidity, recorded at 24 hours and two weeks.

Completion date

01/01/2004

Eligibility

Key inclusion criteria

- 1. It is clear that they need acute intramuscular sedation because of disturbed and dangerous behaviour thought to be due to serious mental illness; and
- 2. The clinician is uncertain about the benefits and risks of the comparator medications.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Total final enrolment

301

Key exclusion criteria

People are not eligible for trial entry if the clinician believes that one treatment represents an additional risk for the patient.

Date of first enrolment

01/01/2003

Date of final enrolment

01/01/2004

Locations

Countries of recruitment

Brazil

Study participating centre Oswaldo Cruz Foundation

Rio de Janeiro Brazil RJ 21041-210

Sponsor information

Organisation

Oswaldo Cruz Foundation (Brazil)

ROR

https://ror.org/04jhswv08

Funder(s)

Funder type

Government

Funder Name

There are no specific extramural funds.

Funder Name

The British Council (UK) - facilitated international contact

Funder Name

CAPES Foundation (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) (Brazil) - facilitated international contact

Funder Name

The Ministry of Health (Brazil) - seconded the principal investigator for 2 years

Funder Name

Regional Health Authorities (Brazil) - donated drugs

Funder Name

The Cochrane Schizophrenia Group (UK) - supported with funding for sundries

Funder Name

The doctors and nurses of Rio freely gave support, enthusiasm and skill.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	27/09/2003	21/05/2019	Yes	No
Protocol article	protocol	16/10/2002		Yes	No